...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: ZEN-3694 Single Agent Trial Status

Thanks bear for outlining what is known about the trial events. That is very helpful.

I think if there were breakthrough results we'd be receiving updates. I believe this is their first clinical forray into cancer. As you have outlined there are many factors in this trial including maximum dosing, continuous dosing vs intermitant, on it's own vs with enzalutimide, sample size, time, recruiting,etc.

It is never fun to live with mushroom management but that is our situation. If something big was happening we'd know. This is just the beginning of the journey IMHO.

Toinv

6
Oct 24, 2017 11:18AM
1
Oct 25, 2017 09:02AM
2
Oct 26, 2017 10:24AM
5
Oct 26, 2017 12:13PM

Nov 02, 2017 03:38PM

Nov 02, 2017 04:29PM

Nov 03, 2017 10:49AM

Nov 03, 2017 10:58AM

Nov 03, 2017 12:07PM
2
Nov 03, 2017 03:45PM
2
Nov 03, 2017 04:23PM
5
Nov 18, 2017 07:45PM
Share
New Message
Please login to post a reply